Nadine Jahchan

Company: Pionyr Immunotherapeutics

Job title: Director

Seminars:

Targeting Immunosuppressive MARCO+ Myeloid Cells to Unleash Anti-Tumor Immunity 3:45 pm

Pionyr identified the Macrophage Receptor with a Collagenous Structure (MARCO) as a potential myeloid reprogramming target and developing a humanized  anti-MARCO monoclonal antibody (mAb), termed PY265 PY265 induced reprogramming of M2-like macrophages and immunosuppressive mMDSCs to M1-like  macrophages and pro-inflammatory monocytes, leading  to pro-inflammatory immune activation PY265m, a surrogate antibody specific to mouse MARCO, demonstrated significant…Read more

day: Day One